![]() ![]() Prof Ildiko Lingavav, MD, Andrei-Mircea Catarig, MD, Juan P Frias, MD et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. For more information, visit novonordisk.ca, Twitter or YouTube.ġ. Headquartered in Denmark, Novo Nordisk employs approximately 41,700 people in 77 countries and markets its products in more than 165 countries. ![]() This heritage has given us experience and capabilities that also enable us to help people defeat obesity, hemophilia, growth disorders and other serious chronic diseases. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. In this trial, there was a 26% cardiovascular risk reduction in Ozempic ® treated patients with type 2 diabetes at high cardiovascular risk, regardless of event history, gender or age. Ozempic ® demonstrated cardiovascular safety in SUSTAIN 6. 1,2,3 The SUSTAIN 7 trial included 1201 patients and was conducted to compare the efficacy and safety of Ozempic ® 0.5mg and 1mg once weekly versus dulaglutide 0.75 mg and 1.5 mg once weekly (SUSTAIN 7). Ozempic ® demonstrated superior glycemic control versus other treatments: sitagliptin (SUSTAIN 2), dulaglutide (SUSTAIN 7) and canagliflozin (SUSTAIN 8). SUSTAIN is a global clinical trial program for Ozempic ® comprised of phase 3a clinical trials and a cardiovascular outcomes trial, involving more than 8,000 adults with type 2 diabetes. Ozempic ® is available through many private insurance plans and publicly reimbursed through the following national and provincial government-sponsored drug benefit programs: 1įor information about Ozempic ®, including important safety information, please visit NovoNordisk.ca or Ozempic.ca. Ozempic ® had a well-tolerated profile across the SUSTAIN clinical trial program with the most common adverse events being generally mild to moderate gastrointestinal disorders, which diminished over time. 1 Ozempic ® is available in a prefilled pen, based on the latest generation of Novo Nordisk prefilled devices. ![]() Ozempic ® is a once-weekly analogue of human GLP-1 designed to mimic natural sugar metabolism by stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner. "We believe that Ozempic ® has the potential to further improve the treatment of adults living with type 2 diabetes and we thank the Ontario government for their commitment to offering Canadians with type 2 diabetes innovative treatment options." "Type 2 diabetes impacts a person's quality of life, and if blood glucose levels remain high, it can also be life-threatening," says Vicky Chan, Vice President, Clinical Development, Medical and Regulatory Affairs, Novo Nordisk Canada. Being able to prescribe Ozempic ®, which patients only need to take once a week, is an important step in helping to control the condition and reduce those risks." "When left uncontrolled, diabetes can cause serious health problems that can negatively impact a person's quality of life. Ronald Goldenberg, an endocrinologist affiliated with LMC Healthcare and North York General Hospital. "Having public access to effective treatment options is essential for people living with type 2 diabetes," explains Dr. 1 In the SUSTAIN program, Ozempic ® was studied in combination with oral-antidiabetic agents and basal insulin. Ozempic ® was extensively studied in the SUSTAIN clinical trial program, which involved more than 8,000 adults with type 2 diabetes. This announcement follows the regulatory approval of Ozempic ® in January of 2018. Ozempic® (semaglutide injection) product image. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |